Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the interest coverage ratio high or low?
The interest coverage ratio of -11.95x is 25% below its 5-year average of -9.56x, near the high end of its 5-year range (-72.52x–-5.80x).
44.06% above its 12-month average of -21.36x.
Reported quarterly interest coverage; no daily interpolation. Q4 FY2025 (2025-12-31): -72.52x.
INTEREST COVERAGE RATIO
-11.95x
INTEREST COVERAGE RATIO AVG TTM
-21.36x
INTEREST COVERAGE RATIO AVG 3Y
-7.35x
INTEREST COVERAGE RATIO AVG 5Y
-9.56x
INTEREST COVERAGE RATIO AVG 10Y
-18.53x
INTEREST COVERAGE RATIO AVG 15Y
N/A
INTEREST COVERAGE RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+44.06%
CURRENT VS 3Y AVG
-62.58%
CURRENT VS 5Y AVG
-25.04%
CURRENT VS 10Y AVG
+35.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-5.54x
median of 432 covered companies
CURRENT VS SECTOR MEDIAN
-115.70%
vs the sector median at left
KALA BIO, Inc.
Market Cap
$7.28M
Interest Coverage Ratio
-11.95x
TTM Avg
-21.36x
3Y Avg
-7.35x
5Y Avg
-9.56x
Market Cap
$7.26M
Interest Coverage Ratio
-496.55x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.31M
Interest Coverage Ratio
-924.78x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.98M
Interest Coverage Ratio
-185.05x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.13M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.01M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.59M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.90M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| KALA BIO, Inc. (KALA) | $7.28M | -11.95x | -21.36x | -7.35x | -9.56x |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.26M | -496.55x | N/A | N/A | N/A |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | -924.78x | N/A | N/A | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $6.98M | -185.05x | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.13M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.47M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.01M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.59M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.90M | N/A | N/A | N/A | N/A |
| GT Biopharma, Inc. (GTBP)vs › | $7.83M | -97.81x | N/A | N/A | N/A |
Interest Coverage
-11.9x
Debt/Equity
0.00
Current Ratio
6.88
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | INTEREST COVERAGE RATIO |
|---|---|
| 2025-12-31 | -72.52x |
| 2025-09-30 | -7.52x |
| 2025-06-30 | -10.20x |
| 2025-03-31 | -9.78x |
| 2024-12-31 | -6.80x |
| 2024-09-30 | -6.47x |
| 2024-06-30 | -6.61x |
| 2024-03-31 | -8.09x |
| 2023-12-31 | -6.36x |
| 2023-09-30 | -7.20x |
| 2023-06-30 | -6.54x |
| 2023-03-31 | -6.83x |
| 2022-12-31 | -5.80x |
| 2022-09-30 | -10.04x |
| 2022-06-30 | -12.15x |
| 2022-03-31 | -15.16x |
| 2021-12-31 | -12.53x |
| 2021-09-30 | -12.58x |
| 2021-06-30 | -13.89x |
| 2021-03-31 | -13.22x |
| 2020-12-31 | -13.36x |
| 2020-09-30 | -11.98x |
| 2020-06-30 | -9.97x |
| 2020-03-31 | -9.46x |
| 2019-12-31 | -9.42x |
| 2019-09-30 | -9.89x |
| 2019-06-30 | -10.87x |
| 2019-03-31 | -11.49x |
| 2018-12-31 | -11.22x |
| 2018-09-30 | -35.87x |
| 2018-06-30 | -35.07x |
| 2018-03-31 | -30.35x |
| 2017-12-31 | -27.78x |
| 2017-09-30 | -44.97x |
| 2017-06-30 | -46.30x |
| 2017-03-31 | -48.34x |
| 2016-12-31 | -40.78x |
| 2016-09-30 | -52.40x |
| 2016-06-30 | -51.88x |
| 2016-03-31 | -26.16x |
| 2015-12-31 | -25.86x |
